Atyr pharma inc (LIFE)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

39,453

9,210

17,341

14,507

12,965

22,962

31,547

19,272

21,936

21,091

29,765

35,915

28,900

38,388

34,332

43,191

54,099

53,025

60,053

63,066

54,512

13,899

Available-for-sale investments

10,376

21,934

20,723

27,891

30,054

26,583

24,414

45,057

52,164

64,028

60,616

21,306

33,034

33,759

36,198

40,735

-

42,510

-

-

-

-

Collaboration receivable

-

-

-

-

630

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31,949

-

48,750

39,891

-

1,954

Investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Prepaid expenses and other assets

545

781

1,080

1,473

1,095

1,258

1,684

1,668

1,906

1,866

1,825

1,877

1,848

2,621

3,117

1,964

1,575

2,415

2,578

3,218

657

656

Total current assets

50,374

31,925

39,144

43,871

44,744

50,803

57,645

65,997

76,006

86,985

92,206

59,098

63,782

74,768

73,647

85,890

87,623

97,950

111,381

106,175

55,169

16,509

Available-for-sale investments, long-term

-

-

-

-

-

-

-

-

-

-

-

-

-

4,002

10,329

12,655

-

29,814

-

-

-

-

Long-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25,557

-

28,010

44,738

-

-

Property and equipment, net

1,281

1,270

1,386

1,512

1,692

1,853

2,039

2,221

2,374

2,280

2,191

2,003

1,623

1,421

1,596

1,766

1,845

1,793

1,841

2,022

1,839

1,925

Right-of-use assets

2,643

2,821

2,994

3,164

3,323

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

149

172

221

215

156

90

90

90

90

90

90

371

330

333

353

175

100

118

137

146

2,897

2,210

Total assets

54,447

36,188

43,745

48,762

49,915

52,746

59,774

68,308

78,470

89,355

94,487

61,472

65,735

80,524

85,925

100,486

115,125

129,675

141,369

153,081

59,905

20,644

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

748

847

1,324

664

834

1,040

599

832

1,462

2,276

3,592

2,669

1,246

2,606

3,565

4,723

5,876

3,872

1,590

3,002

3,168

1,433

Accrued expenses

1,908

2,376

1,579

1,582

1,239

2,026

2,382

2,535

2,533

3,103

3,861

4,194

4,160

5,450

-

-

3,568

4,595

3,569

2,817

2,645

2,932

Contract liability

143

208

352

536

630

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of operating lease liability

780

755

729

705

681

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,520

5,414

-

-

-

-

-

-

Current portion of deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

49

130

211

291

320

315

310

305

300

295

Current portion of long-term debt, net of issuance costs and discount

6,866

8,737

7,844

7,817

7,791

7,767

7,742

7,717

7,027

5,012

2,267

2,786

1,094

339

-

-

-

3,366

-

-

-

-

Current portion of commercial bank debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,640

3,489

3,427

-

3,307

3,248

3,190

3,134

Convertible promissory note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,000

2,000

Preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

242

319

Total current liabilities

10,445

12,923

11,828

11,304

11,175

10,833

10,723

11,084

11,022

10,391

9,720

9,649

6,549

8,525

11,936

13,917

13,191

12,148

8,776

9,372

11,545

10,113

Long-term operating lease liability, net of current portion

2,035

2,239

2,439

2,632

2,815

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

130

211

291

369

445

Long-term debt, net of current portion and issuance costs and discount

-

-

2,742

4,600

6,440

8,263

10,065

11,848

12,950

14,719

12,479

11,792

8,480

9,198

-

-

-

1,776

-

-

-

-

Commercial bank debt, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

896

-

2,640

3,489

4,322

5,142

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

557

571

585

588

380

335

Commitments and contingencies (Note 4)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Redeemable convertible preferred stock, $0.001 par value; authorized shares  7,285,456 at September 30, 2016 and December 31, 2015; issued and outstanding shares  none at September 30, 2016 and December 31, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

141,295

95,619

Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares – 0 and 1,643,961 as of March 31, 2020 (unaudited) and December 31, 2019, respectively

-

2

2

2

2

2

2

2

2

2

2

-

-

-

0

0

0

-

-

-

-

0

Common stock, $0.001 par value per share; 10,714,286 authorized shares; issued and outstanding shares – 9,352,498 and 3,891,787 as of March 31, 2020 (unaudited) and December 31, 2019, respectively

9

4

50

49

37

2

30

30

30

30

30

24

24

24

24

24

24

24

24

24

1

1

Additional paid-in capital

362,723

343,524

343,048

340,893

334,324

332,407

331,390

330,694

329,455

328,519

325,031

-

-

278,832

-

-

-

-

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

281,586

280,134

-

277,371

276,120

274,638

273,321

270,832

269,725

21,215

19,209

Stockholder note receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

Accumulated other comprehensive loss

-53

-40

-33

-32

-40

-60

-57

-85

-136

-120

-63

-57

-68

-76

7

19

-19

-171

-68

-106

-

-

Accumulated deficit

-320,551

-322,304

-316,331

-310,686

-304,838

-298,701

-292,379

-285,265

-274,853

-264,186

-252,712

-241,522

-229,384

-215,979

-203,413

-189,594

-174,211

-158,124

-141,631

-130,302

-119,222

-110,151

Total aTyr Pharma stockholders’ equity

42,128

21,186

26,736

30,226

29,485

33,650

38,986

45,376

54,498

64,245

72,288

40,031

50,706

62,801

73,989

86,569

100,432

115,050

129,157

139,341

-98,006

-91,010

Noncontrolling interest in Pangu BioPharma Limited

-161

-160

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total stockholders' equity

41,967

21,026

-

-

-

33,650

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total liabilities and stockholders’ equity

54,447

36,188

43,745

48,762

49,915

52,746

59,774

68,308

78,470

89,355

94,487

61,472

65,735

80,524

85,925

100,486

115,125

129,675

141,369

153,081

59,905

20,644